Product Info

670G Performance Data and
Technical Information
I. Performance data for users 14 years old and older
A. Device performance for users 14 years and older
The MiniMed 670G System can automatically increase or decrease insulin delivery
when informed by continuous glucose monitoring (CGM) values; however, the user
must still calculate and administer meal boluses. Previous clinical studies that did
not involve the MiniMed 670G System have shown that other integrated insulin
pump and CGM systems may provide better diabetes management, compared
with multiple daily injections or with the pump alone. Some studies also suggest
that when you pair pump therapy with the information provided by the sensor, it
may significantly improve HbA1C levels without increasing the risk of
hypoglycemia.
1, 2, 3
The MiniMed 670G System also features SmartGuard technology with different
types of diabetes management. There are two levels of SmartGuard technology:
• The first level of SmartGuard technology automatically suspends insulin when
the sensor reaches a preset low limit or before the low limit is reached,
referred to as Suspend on low and Suspend before low, respectively. When a
1 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump
therapy in type 1 diabetes [STAR3 Study]. N Engl J Med.2010;363:311–320.
2 Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1
diabetes treated with insulin pump therapy [SWITCH study]. Diabetologia. 2012 Dec;55(12):3155-62. doi:
10.1007/s00125-012‐2708‐9. Epub 2012 Sept 11.
3 Bergenstal RM, Klonoff DC, Bode BW, et al. Threshold-based insulin-pump interruption for reduction of
hypoglycemia [ASPIRE in-home study]. N Engl J Med. 2013;369(3):224-232.
670G Performance Data and Technical Information 323
■
670G Performance Data and Technical Information